Cipla posts 7% year-on-year rise in Q2 PAT, riding on 10% revenue growth

Sequentially, however, the company has posted muted growth-revenue growth of 0.3%, and a PAT decline of 0.5%. Ebitda dipped sequentially too, by 9%

Mumbai-based Cipla, which has a wide portfolio of Covid-19 drugs, posted a 7 per cent year-on-year (YoY) rise in profit after tax (PAT) in the second quarter of the fiscal riding on 10 per cent YoY growth in revenues.

Cipla posted a PAT of Rs 711 crore, and revenue from operations of Rs 5,520 crore during the quarter. The Ebitda came in at Rs 1,226 crore, up 4 per cent YoY, with a resulting Ebitda margin of 22.2 per cent.

Umang Vohra MD and Global CEO, Cipla said that ‘strong momentum’ continued in core therapies across its branded markets, offsetting